Overview
Product name | Recombinant Mouse TNFSF15/TL1A Protein |
---|
Catalog No. | RP01936 |
---|
Description | Recombinant Recombinant Mouse TNFSF15/TL1A Protein is produced by E. coli expression system. The target protein is expressed with sequence (Ile76-Leu252) of Mouse TNFSF15/TL1A (Accession #NP_796345.3) fused with no tag . |
---|
Bio-Activity | Measured by its ability to induce apoptosis of TF‑1 human erythroleukemic cells. The ED50 for this effect is 15.61-62.44 ng/mL, corresponding to a specific activity of 1.60×104~6.41×104 units/mg.
|
---|
Purity | > 95% by SDS-PAGE. |
---|
Endotoxin | <1EU/ug of the protein by LAL method |
---|
Formulation | Lyophilized from 0.22 μm filtered solution in 20mM PB, 300mM NaCl (pH 7.0). Normally 8% trehalose is added as protectant before lyophilization. |
---|
Species | Mouse |
---|
Calculated MW | 19.90 kDa |
---|
Background
TL1A is a type II transmembrane protein belonging to the TNF superfamily and has been designated TNF superfamily member 15 (TNFSF15). Mouse TL1A is a 252 amino acid residues (aa) protein consisting of a 35 aa N-terminal cytoplasmic domain, a 24 aa transmembrane region and 193 aa C-terminal extracellular domain. TL1A is expressed predominantly in endothelial cells and its expression is stimulated by TNF-a and IL-1a. Non-endothelial cells of the gut mucosa, including lamina propria lymphocytes and tissue macrophages, also express TL1A and at higher levels in chronic inflammatory bowel disorders . TL1A binds with high affinity to death receptor 3 (DR3), which is now designated TNF receptor superfamily member 25 (TNFRSF25). DR3 was formerly designated TNFRSF12 when it was thought to be the receptor for TWEAK/TNFSF12. Depending on the cell type, DR3-TL1A interactions have different effects. Ligation of DR3 on activated T cells by TL1A provides a costimulatory signal to increase IL-2 responsiveness and the secretion of proinflamatory cytokines . The promotion of survival of activated T cells by TL1a results from the activation of the transcription factor NF-kappa-B. In a tumor erythroleukemic cell line, TF-1, DR3-TL1A signaling increases production of the NF-kB-dependent antiapoptotic protein c-IAP2, promoting survival in these cells . In HUVEC cells, which express both DR3 and TL1A, ligation of DR3 by TL1A regulates cell apoptosis . These effects of TL1A are blocked by the secreted, soluble decoy receptor 3 (DcR3), also known as TR6 and TNFRSF6B, which compete with DR3 for binding to TL1A . Consistent with the observed in vitro activities, TL1A promotes ex vivo splenocyte expansion and enhances in vivo graft-versus-host-response. The level of TL1A in cells of gut mucosa, in patients with bowel inflammatory disorders, correlates with the severity of inflammation, and TL1A may play a role in a Th1-mediate pathological conditions such as Crohn’s disease .
Product information
Synonym | Tnfsf15; Tl1; Vegi; Tumor necrosis factor ligand superfamily member 15; TNF ligand-related molecule 1; Vascular endothelial cell growth inhibitor |
---|
Expression Host | E. coli |
---|
Tag | NO-Tag |
---|
Swiss-Prot | |
---|
Gene ID | |
---|
Usage guide
Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
---|
Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
---|
* For research use only. Not for therapeutic or diagnostic purposes.